Mumbai, November 14, 2025: Lupin Limited has announced that it has secured an S&P Global ESG Score of 91 for 2025, placing the company among a select group of global pharmaceutical organisations that have crossed the 90-point threshold. The achievement stands significantly higher than the pharmaceutical industry average score of 28.
According to Lupin, the company’s ESG rating has risen sharply from a score of 17 in 2021—one of the fastest improvements recorded in the sector. The company stated that this progress reflects sustained efforts across environmental, social and governance pillars, aligning with global standards for sustainable business practices.
Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, “Achieving a score above 90 in the S&P Global ESG ratings is rare global distinction, highlighting our unwavering commitment to sustainability. With a 15-point increase from last year, Lupin not only leads the pharmaceutical industry today, but redefines and sets new standards for responsible growth. Our purpose-led strategy ensures that we provide healthcare solutions that generate lasting value for patients, communities, and stakeholders worldwide.”
The company highlighted advances in renewable energy adoption, reduction of carbon emissions and attaining water-positive operations as part of its environmental progress. On the social front, Lupin has strengthened initiatives in employee well-being, diversity and inclusion, and community healthcare outreach.
In governance, Lupin has implemented stronger transparency frameworks, enhanced ethical practices, and introduced board-level oversight mechanisms to address ESG-related risks and opportunities.
Lupin operates in over 100 markets and maintains 15 manufacturing sites and seven research centres worldwide. The company continues to expand its offerings across therapeutic areas while embedding sustainability within its business operations.
The improved ESG score reinforces Lupin’s stated commitment to responsible growth and positions it as a global leader in sustainable pharmaceutical practices.
x
.jpg)
